| __timestamp | Taro Pharmaceutical Industries Ltd. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 179279000 | 5903000 |
| Thursday, January 1, 2015 | 186359000 | 2762000 |
| Friday, January 1, 2016 | 171785000 | 1114000 |
| Sunday, January 1, 2017 | 208136000 | 25573000 |
| Monday, January 1, 2018 | 198405000 | 6000000 |
| Tuesday, January 1, 2019 | 224169000 | 38845000 |
| Wednesday, January 1, 2020 | 245044000 | 50523000 |
| Friday, January 1, 2021 | 252314000 | 75463000 |
| Saturday, January 1, 2022 | 268225000 | 105767000 |
| Sunday, January 1, 2023 | 304629000 | 167512000 |
| Monday, January 1, 2024 | 324203000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Xenon Pharmaceuticals Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro consistently outperformed Xenon in managing its cost of revenue, with Taro's costs increasing by approximately 81% over the period. In contrast, Xenon saw a staggering increase of over 2,700% in its cost of revenue, highlighting a significant challenge in cost management.
Taro's cost efficiency is evident, with a steady rise from 2014's $179 million to 2023's $305 million. Meanwhile, Xenon's costs surged from a modest $5.9 million in 2014 to $167 million in 2023. This stark contrast underscores the importance of strategic financial management in the pharmaceutical industry, where every dollar counts.
Analyzing Cost of Revenue: Novartis AG and Taro Pharmaceutical Industries Ltd.
Cost of Revenue Comparison: Biogen Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Viatris Inc. and Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Bio-Techne Corporation and Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Xenon Pharmaceuticals Inc.'s Expenses
Walgreens Boots Alliance, Inc. vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Pharming Group N.V. and Taro Pharmaceutical Industries Ltd.
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Taro Pharmaceutical Industries Ltd.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Geron Corporation vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.